| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLEC4K |
| Uniprot No | Q9UJ71 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 65-328aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSPRFMGTI SDVKTNVQLL KGRVDNISTL DSEIKKNSDG MEAAGVQIQM VNESLGYVRS QFLKLKTSVE KANAQIQILT RSWEEVSTLN AQIPELKSDL EKASALNTKI RALQGSLENM SKLLKRQNDI LQVVSQGWKY FKGNFYYFSL IPKTWYSAEQ FCVSRNSHLT SVTSESEQEF LYKTAGGLIY WIGLTKAGME GDWSWVDDTP FNKVQSARFW IPGEPNNAGN NEHCGNIKAP SLQAWNDAPC DKTFLFICKR PYVPSEP |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLEC4K重组蛋白的模拟参考文献(内容基于已有知识框架模拟，建议通过学术数据库核实具体文献)：
---
1. **文献名称**: *"Recombinant CLEC4K mediates pathogen recognition through carbohydrate binding"*
**作者**: Smith A, et al.
**摘要**: 本研究成功表达并纯化了CLEC4K重组蛋白，证实其通过C型凝集素结构域特异性结合病原体表面甘露糖化糖蛋白，揭示了其在先天免疫中识别病原体的分子机制。
2. **文献名称**: *"Structural and functional analysis of CLEC4K in dendritic cell signaling"*
**作者**: Tanaka Y, et al.
**摘要**: 通过X射线晶体学解析了重组CLEC4K的胞外结构域三维结构，结合功能实验表明其通过钙离子依赖性糖基结合激活树突状细胞的抗原呈递通路。
3. **文献名称**: *"CLEC4K recombinant protein suppresses T-cell activation via interaction with CD44"*
**作者**: Lee H, et al.
**摘要**: 发现重组CLEC4K蛋白可通过结合T细胞表面CD44分子抑制过度免疫反应，提示其在自身免疫性疾病治疗中的潜在应用价值。
4. **文献名称**: *"High-yield production of bioactive CLEC4K in mammalian expression systems"*
**作者**: Zhang R, et al.
**摘要**: 优化了CLEC4K在哺乳动物细胞中的重组表达条件，获得高纯度糖基化蛋白，并验证其与天然蛋白相似的生物活性，为后续功能研究提供可靠工具。
---
**注**：以上文献信息为模拟生成，实际引用请通过PubMed/Google Scholar等平台以关键词“CLEC4K recombinant”或“CLEC4A1 protein”检索。
**Background of Recombinant CLEC4K Protein**
CLEC4K (C-type lectin domain family 4 member K), also known as CLEC4A or CD369. is a transmembrane protein belonging to the C-type lectin receptor (CLR) family. These receptors play critical roles in immune regulation, pathogen recognition, and homeostasis. CLEC4K is primarily expressed on dendritic cells (DCs) and macrophages, where it functions as a pattern recognition receptor (PRR). It binds to carbohydrate structures on pathogens, such as fungi and viruses, through its carbohydrate-recognition domain (CRD), facilitating pathogen uptake and modulating immune responses.
Recombinant CLEC4K protein is engineered in vitro using expression systems like mammalian cells (e.g., HEK293) or bacteria (e.g., *E. coli*), enabling large-scale production for research and therapeutic applications. The recombinant form typically retains the CRD, crucial for ligand binding, and may include tags (e.g., Fc or His tags) for purification and detection. Its structure often mimics native glycosylation patterns when produced in mammalian systems, which is essential for functional studies.
Research on recombinant CLEC4K focuses on elucidating its role in immune signaling. It interacts with ligands like high-mannose glycans, triggering downstream pathways that influence cytokine production, antigen presentation, and T-cell activation. Studies also explore its involvement in autoimmune diseases, infections, and cancer, where dysregulated CLEC4K expression correlates with altered immune responses.
Current applications include using recombinant CLEC4K as a tool to study receptor-ligand interactions, develop targeted immunotherapies, or design vaccines by exploiting its pathogen-binding properties. Challenges remain in understanding its precise signaling mechanisms and tissue-specific functions, but ongoing work highlights its potential as a therapeutic target or diagnostic biomarker in immune-related disorders.
×
